News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Galapagos Genomics NV Expects 4Q ’05 Revenues To Meet Guidance, Reduced Full Year 2005 Cash Burn
January 18, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Galapagos (Euronext & LSE: GLPG) announced today that it expects fourth quarter 2005 consolidated revenues to meet previous guidance of € 7.7 million, and full year cash burn for 2005 to be lower than guidance of € 7 million.
Twitter
LinkedIn
Facebook
Email
Print
Europe
MORE ON THIS TOPIC
Europe
AstraZeneca Suspends $270M UK Commitment Months After Scrapping Vaccine Facility
September 15, 2025
·
2 min read
·
Tristan Manalac
IN PARTNERSHIP WITH CRESSET
Why AI Won’t Save the 90% of Clinical Trials That Still Fail
August 21, 2025
·
1 min read
·
Lori Ellis
Drug pricing
Lilly Aims To Raise Europe Drug Prices in Response to Trumps’ Most Favored Nation Policy
August 14, 2025
·
3 min read
·
Annalee Armstrong
Earnings
Lilly Faces Triple Threat of Drug Pricing Pressure as CEO Emphasizes Value
August 7, 2025
·
3 min read
·
Annalee Armstrong